Co-Diagnostics, Inc. Share Price

Equities

CODX

US1897631057

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
1.11 USD -2.63% Intraday chart for Co-Diagnostics, Inc. -3.48% -16.54%
Sales 2024 * 5.82M 466M Sales 2025 * - Capitalization 34.7M 2.78B
Net income 2024 * -31M -2.48B Net income 2025 * - EV / Sales 2024 * 5.96 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.12 x
P/E ratio 2025 *
-
Employees 155
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.63%
1 week-3.48%
Current month-0.89%
1 month-0.45%
3 months-11.90%
6 months+3.74%
Current year-16.54%
More quotes
1 week
1.11
Extreme 1.11
1.18
1 month
1.07
Extreme 1.0689
1.29
Current year
1.02
Extreme 1.02
1.50
1 year
0.98
Extreme 0.975
1.89
3 years
0.98
Extreme 0.975
11.82
5 years
0.69
Extreme 0.694
30.99
10 years
0.69
Extreme 0.694
30.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 17/04/13
Director of Finance/CFO 48 21/02/21
Chief Tech/Sci/R&D Officer - 31/10/22
Members of the board TitleAgeSince
General Counsel 77 31/10/14
Director/Board Member 79 30/04/17
Chief Executive Officer 70 17/04/13
More insiders
Date Price Change Volume
26/04/24 1.11 -2.63% 22,634
25/04/24 1.14 0.00% 15,357
24/04/24 1.14 -0.87% 32,978
23/04/24 1.15 0.00% 10,270
22/04/24 1.15 0.00% 26,328

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.11 USD
Average target price
2.5 USD
Spread / Average Target
+125.23%
Consensus